The Power of Public Science: Lessons from TV003 and Butantan-DV
Clicks: 5
ID: 323047
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
5 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #238 of 431 articles by views in The Journal of infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 431 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Butantan-DV, a single-dose dengue vaccine based on NIH's TV003, was licensed in Brazil after 20+ years of public investment. This Perspective argues its success demonstrates the indispensable value of sustained public funding for global vaccine development
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (35 words).
Try re-searching for a better abstract.
| Reference Key |
openalex_W7171815350
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Felippe Lazar Neto, Anna P. Durbin |
| Journal | The Journal of infectious diseases |
| Year | 2026 |
| DOI |
10.1093/infdis/jiag396
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.